Lv1
50 积分 2024-01-10 加入
In vivo CAR engineering for immunotherapy
1天前
已完结
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas
5个月前
已关闭
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas
5个月前
已关闭
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas
5个月前
已关闭
Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1
10个月前
已完结
T Cell Receptor Repertoire in Rheumatoid Arthritis
1年前
已完结
Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?
1年前
已完结
Ankylosing spondylitis
1年前
已完结
Preclinical assessment of LCAR-B38M, a novel BCMA-targeting chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory multiple myeloma
1年前
已完结
Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy
1年前
已完结
皖公网安备34019202002308
